Formosa Pharmaceuticals Inc

Formosa Pharmaceuticals Inc has a current ratio of 4.58, indicating strong short-term liquidity, but its operating cash flow is negative at -53,728,000 TWD, and free cash flow is also negative at -9,433,000 TWD. The company's debt-to-equity ratio is 0.03, suggesting a conservative capital structure with minimal leverage. The company's profitability is weak, with a return on equity of -1.76% and a return on assets of -1.12%, both significantly below the industry median for pharmaceutical companies. This underperformance is reflected in its net income of -19,471,000 TWD, despite a high gross profit of 111,825,000 TWD. Formosa Pharmaceuticals Inc's revenue is concentrated in the Asia-Pacific region, with no disclosed segment breakdown in the latest financial data. The company's exposure to this region may pose risks due to regulatory changes or economic volatility. The company's growth trajectory is uncertain, with no disclosed revenue growth or decline in the latest financial data. However, its operating income of 13,379,000 TWD suggests some level of operational efficiency. The company faces liquidity risks due to its negative operating and free cash flows, despite a low debt-to-equity ratio. There is no indication of dilution risk in the near term, as shares outstanding remain unchanged between basic and diluted shares. Recent filings and transcripts do not indicate any major strategic shifts or new product launches. The company's financial performance and risk profile suggest a need for operational improvements to restore profitability and strengthen cash flow.